Park, Ko Un
Padamsee, Tasleem J.
Birken, Sarah A.
Lee, Sandy
Niles, Kaleigh
Blair, Sarah L.
Grignol, Valerie
Dickson-Witmer, Diana
Nowell, Kerri
Neuman, Heather
King, Tari
Mittendorf, Elizabeth
Paskett, Electra D.
Brindle, Mary
Funding for this research was provided by:
National Cancer Institute (202010121, K08CA263488, UG1CA189823, UG1CA189824, UG1CA233180, UG1CA233277, UG1CA233331)
Article History
Received: 3 April 2024
Accepted: 9 May 2024
First Online: 11 June 2024
Disclosure
: Electra D. Paskett was supported by MPI on grants to the institution from Pfizer, Merck Foundation, Genentech, and Guardant Health and is a consultant for Merck and GSK, none of which was related to this work. Tari King received speaker honoraria and has an advisory board role for Exact Sciences. Elizabeth Mittendorf is compensated for service on scientific advisory boards for Astra Zeneca, BioNTech, Merck and Moderna and provides uncompensated service on steering committees for Bristol Myers Squibb, and Roche/Genentech, as well as institutional research support from Roche/Genentech (via SU2C grant), and Gilead. She also reports research funding from Susan Komen for the Cure, for which she serves as a Scientific Advisor, as well as uncompensated participation as a member of the American Society of Clinical Oncology Board of Directors. The remaining authors have no conflicts of interest.